Dr Reddy's Laboratories (DRL) and Torrent Pharmaceuticals entered into an agreement today for exclusive commercialisation of two of Torrent's brands in Russia. The two brands - Listril (Lisinopril) and Listril Plus (Lisinopril HCTZ) - are cardiovascular drugs used in the treatment of high blood pressure.The agreement offers the potential for immediate commercialisation of the two brands as they have already been registered in Russia, DRL stated.This is the second agreement that DRL has made with Torrent for the territory of Russia. The first was related to the licensing for Omez D, used to treat gastro-intestinal diseases like heartburn, dyspepsia and epigastric pain, will be launched in Ukraine and Kazakhstan in the short term, followed by Russia and Belarus.
